Pre-made Anifrolumab benchmark antibody ( Whole mAb, anti-IFNAR1 therapeutic antibody, Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-026-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody
INN Name	Anifrolumab
Target	IFNAR1
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	4qxg:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Medarex;Medical University of Vienna;MedImmune
Conditions Approved	Systemic lupus erythematosus
Conditions Active	Lupus nephritis
Conditions Discontinued	Scleroderma
Development Tech	Medarex UltiMAb Mouse